Kalvista Pharmaceuticals
Presence
Kalvista Pharmaceuticals is one of the...
Kalvista Pharmaceuticals is a company listed under the stock ticker KALV (US).
Executives
View the org chart displaying its 15 main executives
Most searched biographies at Kalvista Pharmaceuticals
- Benjamin Palleiko, Chief Executive Officer and Director
- Pat Treanor, Director
- Edward Unkart, Director
Popular executive movements at Kalvista Pharmaceuticals
- William Fairey has joined the company as Director (posted on April 23 2024).
- Benjamin Palleiko, who was President, Chief Financial Officer and Chief Business Officer, is promoted to Chief Executive Officer and Director (posted on March 8 2024).
- Andrew Crockett, Chief Executive Officer and Director, has left the company (posted on March 8 2024).
Create your alert
to follow the executive moves at Kalvista Pharmaceuticals.
Pharmaceuticals
Kalvista Pharmaceuticals has 1,860 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Kalvista Pharmaceuticals
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KalVista Pharmaceuticals, Inc.
- KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference | KalVista Pharmaceuticals, Inc.
- News Releases | KalVista Pharmaceuticals, Inc.
- News Releases | KalVista Pharmaceuticals, Inc.
- News Releases | KalVista Pharmaceuticals, Inc.
- KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results | KalVista Pharmaceuticals, Inc.
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KalVista Pharmaceuticals, Inc.
- KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program | KalVista Pharmaceuticals, Inc.
- News Releases | KalVista Pharmaceuticals, Inc.
- News Releases | KalVista Pharmaceuticals, Inc.
- View more press releases Close
Social media about Kalvista Pharmaceuticals
- Kalvista Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Kalvista Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Benjamin Palleiko 
Call Kalvista Pharmaceuticals at +1 857...
